孟鲁司特钠联合干扰素雾化吸入对学龄期肺炎患儿免疫功能及炎症因子水平的影响

Abstract
Figure/Table
References (21)
Related Citation (15)

Download: PDF (442 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Montelukast Sodium combined with interferon aerosol inhalation on immune function and levels of inflammatory factors in school-age children with pneumonia.Methods A total of 80 school-age children with pneumonia admitted to the Fifth Hospital of Xiamen from June 2022 to June 2023 were selected as the study objects,and they were divided into control group (40 cases) and observation group (40 cases) according to the random number table method.The children in the control group were treated with Montelukast Sodium,and the children in observation group were given Montelukast Sodium combined with interferon aerosol inhalation.The changes in immune function cluster of differentiation (CD3+、CD4+、CD8+),serum inflammatory factors (hypersensitive C-reactive protein[hs-CRP],procalcitonin [PCT],interleukin-6 [IL-6],interleukin-2 [IL-2])and oxidative stress (superoxide dismutase[SOD],total antioxidant capacity [T-AOC],advanced oxidative protein products [AOPPs],lipid hydroperoxide [LHP]) were observed and compared between both groups before treatment and after 2 weeks of treatment.The difference in disease condition (pneumonia severity index [PSI])was compared between the two groups after 2 weeks of treatment.Results The levels of CD3+and CD4+after 2 weeks of treatment in observation group were higher than those of the control group,while the level of CD8+was lower than that of the control group,and the differences were statistically significant(P＜0.05).After 2 weeks of treatment,the level of IL-2 in observation group was higher than that of the control group,while the levels of hs-CRP,PCT and IL-6 of the observation group were lower than those of the control group,with statistical differences (P＜0.05).After 2 weeks of treatment,the levels of SOD and T-AOC in the observation group were higher than those of the control group,while AOPPs and LHP of the observation group were lower than those in the control group,with statistically significant differences (P＜0.05).After 2 weeks of treatment,the PSI grading in the observation group was lower than that in control group,with a statistical significance (P＜0.05).Conclusion Montelukast Sodium combined with interferon aerosol inhalation can help to enhance the immune function and antioxidant capacity,and improve the disease condition,inflammatory status and tissue oxidative damage in school-age children with pneumonia.

Key words： Montelukast Sodium Interferon Aerosol inhalation School-age children Pneumonia Immune function Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2024/V31/I15/57

[1]	贾艳红，郭芳，武晓圆，等.儿童肺炎支原体诱导的皮疹和黏膜炎临床特征分析[J].首都医科大学学报，2023，44（1）：131-136.
[2]	王爽，陈静，张月馨，等.20299 例儿童肺炎支原体感染临床特征分析[J].国际儿科学杂志，2023，50（5）：340-343.
[3]	叶洪舟，朱焰，施明杰.学龄期儿童难治性肺炎支原体肺炎早期预测模型的建立[J].浙江医学，2022，44（14）：1523-1527.
[4]	李玉娟.学龄期难治性肺炎支原体肺炎临床特点及危险因素分析[J].感染、炎症、修复，2021，22（1）：24-29.
[5]	中华医学会儿科学分会呼吸学组.白三烯受体拮抗剂在儿童常见呼吸系统疾病中的临床应用专家共识[J].中华实用儿科临床杂志，2016，31（13）：973-977.
[6]	范新凤，李艳玲，孙晓宝，等.孟鲁司特钠咀嚼片联合布地奈德混悬液治疗急性期支气管哮喘患儿的临床研究[J].中国临床药理学杂志，2023，39（3）：320-323.
[7]	李向京，杨成胜，李建玲.孟鲁司特钠片联合阿奇霉素注射液治疗小儿肺炎支原体肺炎的临床研究[J].中国临床药理学杂志，2023，39（7）：915-919.
[8]	李青，梁宽，胡梦娇，等.重组人干扰素α1b 雾化吸入联合布地奈德治疗儿童反复上呼吸道感染的临床疗效及对免疫功能的影响[J].海南医学，2023，34（6）：818-821.
[9]	祁卫卫，杨宁，路娟，等.重组人干扰素α1b 通过调控Foxp3 对儿童传染性单核细胞增多症免疫功能的影响[J].中国感染控制杂志，2022，21（4）：346-352.
[10]	张国成，尚云晓.《重组人干扰素-α1b 在儿科的临床应用专家共识》解读[J].中华实用儿科临床杂志，2015，30（16）：1220-1222.
[11]	中华医学会儿科学分会呼吸学组，《中华儿科杂志》编辑委员会.儿童社区获得性肺炎管理指南（2013 修订）（上）[J].中华儿科杂志，2013，51（10）：745-752.
[12]	杨凌婧，高凌云，付泽伟，等.血清降钙素原和CURB-65评分及肺炎严重指数在社区获得性肺炎预后中的预测价值研究[J].中国全科医学，2019，22（5）：522-526.
[13]	廖姮，牛延德，朱晓娟，等.肺部超声诊断儿童社区获得性肺炎动态的价值研究[J].中国临床医学影像杂志，2022，33（4）：240-242，248.
[14]	李飞娜，郑惠文，杨海明，等.基于SAT 技术探讨新冠肺炎疫情下北京地区儿童肺炎支原体感染流行病学特征[J].标记免疫分析与临床，2022，29（7）：1089-1092，1147.
[15]	孔念华，陈爱华，张劲松.小儿定喘口服液联合重组人干扰素α1b 治疗儿童毛细支气管炎的临床研究[J].中国医院用药评价与分析，2020，20（6）：663-666.
[16]	范建荣，毕研龙，范铭兴，等.热毒宁联合雾化重组人干扰素α1b 对儿童呼吸道合胞病毒感染肺炎的疗效及免疫功能影响[J].中华中医药学刊，2021，39（11）：189-192.
[17]	戴莎莎，周凯.重组人干扰素α1b 辅助治疗传染性单核细胞增多症疗效的前瞻性随机对照研究[J].中国当代儿科杂志，2020，22（9）：953-957.
[18]	张辉，李虹媛，张建明.匹多莫德联合重组人干扰素α1b及更昔洛韦治疗EB 病毒相关性传染性单核细胞增多症患儿的效果[J].中国医药导报，2022，19（3）：99-102.
[19]	赵敏，杨华，宫晶.重组人干扰素α-1b 对RSV 感染性肺炎患儿免疫及TLR4 蛋白表达的影响[J].国际呼吸杂志，2022，42（16）：1220-1224.
[20]	陈勇，王湘君，王俊杰，等.重组人干扰素α1b 辅助治疗对传染性单核细胞增多症患儿免疫功能及炎症因子的影响[J].海南医学，2021，32（18）：2382-2384.
[21]	谢海琴，赵璇珠.重组人干扰素α1b 联合奥司他韦治疗小儿流感病毒肺炎疗效的随机对照研究[J].中国医药科学，2021，11（7）：116-118，140.